Cargando…

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma

Multiple myeloma (MM) is an incurable hematological malignancy, although bortezomib has markedly improved its outcomes. Growing clinical evidence indicates that enhancing induced natural killer (NK) or γδ T cells for infusion is useful in the treatment of MM. However, whether combination treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Chao, Jin, Haofan, Li, Min, Zhu, Shan, Zhou, Lei, Jin, Feng, Zhou, Yulai, Xu, Dongsheng, Xu, Jianting, Zhao, Lianjing, Hao, Shanshan, Li, Wei, Cui, Jiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351604/ https://www.ncbi.nlm.nih.gov/pubmed/27992381 http://dx.doi.org/10.18632/oncotarget.13979

Ejemplares similares

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
por: Zingoni, Alessandra, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
por: Jin, Zhenyi, et al.
Publicado: (2020)

Altered expression of ligands for the NKG2D and DNAM-1 activating receptors during HIV-1 infection
por: Vassena, Lia, et al.
Publicado: (2013)

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
por: Han, Bin, et al.
Publicado: (2018)

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors
por: Veneziani, Irene, et al.
Publicado: (2019)

The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells
por: Lee, Young Shin, et al.
Publicado: (2018)

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
por: Sayitoglu, Ece Canan, et al.
Publicado: (2020)

Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands
por: Choi, Haeyoun, et al.
Publicado: (2022)

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells
por: Niu, Chao, et al.
Publicado: (2015)

DNAM-1 controls NK cell activation via an ITT-like motif
por: Zhang, Zhanguang, et al.
Publicado: (2015)

Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells
por: Mantovani, Stefania, et al.
Publicado: (2022)

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells
por: Cerboni, Cristina, et al.
Publicado: (2014)

Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment
por: Paolini, Rossella, et al.
Publicado: (2023)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
por: Cifaldi, Loredana, et al.
Publicado: (2023)

Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection
por: Routes, John M., et al.
Publicado: (2005)

CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition
por: Liu, Meng, et al.
Publicado: (2022)

CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
por: Schiller, Christian B., et al.
Publicado: (2016)

NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors
por: Chitadze, Guranda, et al.
Publicado: (2015)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Renal cell carcinoma escapes NK cell‐mediated immune surveillance through the downregulation of DNAM‐1
por: Tong, Le, et al.
Publicado: (2023)

Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns
por: Haik, Josef, et al.
Publicado: (2015)

Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1
por: Zhou, Zhixia, et al.
Publicado: (2012)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
por: Thompson, Thornton W, et al.
Publicado: (2017)

Inflammatory monocytes and NK cells play a crucial role in DNAM-1–dependent control of cytomegalovirus infection
por: Lenac Rovis, Tihana, et al.
Publicado: (2016)

Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1
por: Walwyn-Brown, Katherine, et al.
Publicado: (2018)

Dynamic of Circulating DNAM-1+ Monocytes and NK Cells in Patients with STEMI Following Primary Percutaneous Coronary Intervention
por: Kumric, Marko, et al.
Publicado: (2022)

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
por: Kondo, Masahiro, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

GSK-3α Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKp30-Dependent Manner
por: Kim, Nayoung, et al.
Publicado: (2021)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor
por: Di Pace, Anna Laura, et al.
Publicado: (2020)

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
por: Leng, Yun, et al.
Publicado: (2022)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?
por: Cifaldi, Loredana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pbts5p6anaohb1eb0m364n51sm